Unilateral versus bilateral stage I neuromodulator lead placement for the treatment of refractory voiding dysfunction
✍ Scribed by Khanh Pham; Michael L. Guralnick; R. Corey O'Connor
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 77 KB
- Volume
- 27
- Category
- Article
- ISSN
- 0733-2467
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Aims
To determine if bilateral S3 lead placement during the stage I trial period improves the “success” rate for advancing to stage II (permanent) sacral neuromodulator placement.
Methods
A retrospective chart review of 124 (20 male and 104 female) patients undergoing stage I sacral neuromodulation (InterStim®, Medtronic, Minneapolis, Minnesota) implantation for the treatment of refractory voiding dysfunction was performed. Patients were divided into two cohorts based on unilateral versus bilateral stage I lead placement in the S3 foramina. Both groups were then evaluated and compared with regards to overall “success”, defined as progression from stage I to stage II placement.
Results
Fifty‐five (44%) patients underwent unilateral stage I lead placement and 69 (56%) received bilateral S3 leads. Successful stage I trials were reported in 32/55 (58%) and 53/69 (76%) of unilateral and bilateral cohorts, respectively (P = 0.03). Five wound infections were reported—2 (3.6%) following unilateral and 3 (4.3%) after bilateral stage I lead placement. No other complications were encountered.
Conclusions
Bilateral stage I neuromodulation trial provides a significantly higher rate of improvement in refractory voiding symptoms to allow for the progress to stage II implantation. Neurourol. Urodynam. 27:779–781, 2008, © 2008 Wiley‐Liss, Inc.